Document:

rcus-ex1028_207.htm

 

EXHIBIT 10.28

 

[***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED

 

AMENDMENT NO. 2 TO
LICENSE AGREEMENT

 

This AMENDMENT NO. 2 (the “Amendment”) is made and entered into as of the date of last signature, by and between Arcus Biosciences, Inc. (“Arcus”), with offices at 3928 Point Eden Way, Hayward, CA 94545, U.S.A., and WuXi Biologics (Cayman) Inc. (“WuXi Biologics”), with an address at Ugland House, Grand Cayman, KY1-1104, Cayman Islands. Arcus and WuXi Biologics may be referred to in this Amendment individually as a “Party” or together as the “Parties.”

WHEREAS, WuXi Biologics and Arcus are parties to the License Agreement dated August 16, 2017, as amended June 27, 2019 (“LICENSE AGREEMENT”); 

WHEREAS, the Parties desire to enter into this Amendment for the purpose of amending the biologics CMC exclusivity period;

NOW THEREFORE, in consideration of the premises and for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, IT IS HEREBY AGREED AS FOLLOWS:

	
 
	
1.
	
Section 3.3 of the License Agreement is hereby amended in its entirety as follows:

“3.3Biologic CMC Services

. Subject to the terms of the Biologics Master Services Agreement by and between Arcus Biosciences, Inc. and WuXi Biologics (Hong Kong) Limited effective January 24, 2017, as it may be amended from time to time (the “Biologics MSA”), WuXi shall be Arcus’ exclusive provider of CMC services for biologic development candidates, including but not limited to cell line development, process development, analytical development, manufacturing of toxicology materials, GMP manufacturing, QC testing and stability services for the period running five (5) years from the Effective Date of the License Agreement, all to be carried out under such Biologics MSA.  The Parties shall negotiate any additional terms in good faith and acting reasonably, taking into account terms previously agreed upon by the Parties for such services for other projects.  WuXi shall commit to annual pricing increase of no more than [***] percent ([***]%) in any one calendar year prior to First Commercial Sale and [***] percent ([***]%) in any one calendar year beginning upon First Commercial Sale for all services rendered under this Section 3.3. Promptly after the Effective Date, the Parties shall 

1

 

negotiate in good faith the terms of, and shall seek to enter into, an amendment to the Biologics MSA, which amendment shall provide for (i) WuXi’s exclusive provision of CMC services as contemplated in this Section 3.3 and (ii) Arcus’ obligations to use WuXi as its exclusive provider of CMC services for biologic development candidates to cease upon any termination of the Biologics MSA due to a material breach thereof and/or upon Arcus’ termination of this Agreement pursuant to Sections 10.2.2(a) or 10.2.3 hereof.”

	
 
	
2.
	
Except as otherwise provided herein, all terms and conditions of the LICENSE AGREEMENT shall remain in effect and unchanged. 

	
 
	
3.
	
This Amendment shall be governed by and construed in accordance with the governing law provision set forth in the LICENSE AGREEMENT. 

	
 
	
4.
	
Any dispute arising from or relating to the subject matter of this Amendment shall be resolved in accordance with the dispute resolution provisions set forth in the LICENSE AGREEMENT.

	
 
	
5.
	
This Amendment may be executed in counterparts, each of which, when executed, shall be deemed to be an original and all of which together shall constitute one and the same document. Execution of a facsimile copy (including PDF) shall have the same force and effect as execution of an original, and a facsimile signature shall be deemed an original and valid signature.

 

 

[Signature page follows]

2

 

IN WITNESS WHEREOF, authorized representatives of the Parties have duly executed this Amendment to be effective as of the last date of signature below.

		
	
ARCUS BIOSCIENCES, INC.
	
WUXI BIOLOGICS (CAYMAN) INC.

	
 

 

By____/s/ Juan C. Jaen____________
	
 

 

By____/s/ Chris Chen________________

	
Name: Juan C. Jaen

Title: President
	
Name:Chris Chen

Title: CEO

	
Date:   02 March 2020
	
Date:   26 February 2020

 

3Exhibit 10b

  

   

  

  
    POWER OF ATTORNEY

    

    

    We, the undersigned directors and/or officers of Lincoln Life & Annuity Company of New York, hereby constitute and appoint Delson R. Campbell, Scott C. Durocher, Kimberly A. Genovese, Daniel P. Herr, Donald E. Keller, Michelle Grindle, Jeffrey L. Smith, Jassmin McIver-Jones, Carolyn Augur and John D. Weber, individually, our true and lawful
      attorneys-in-fact, with full power to each of them to sign for us, in our names and in the capacities indicated below, any Registration Statements and any and all amendments to Registration Statements; including exhibits, or other documents filed on
      Forms N-6 or N-4 or any successors or amendments to these Forms, filed with the Securities and Exchange Commission, under the Securities Act of 1933 and/or Securities Act of 1940, on behalf of the Company in its own name or in the name of one of its
      Separate Accounts, hereby ratifying and confirming our signatures as they may be signed by any of our attorneys-in-fact to any amendment to said Registration Statements as
      follows:

    

    

    Variable Life Insurance Separate Accounts:

    

    

    	
            Lincoln Life & Annuity Flexible Premium Variable Life Account M (811-08559)

          	
            VUL-I / VULcv

            VULcv-II / VUL Flex ES

            VULcv-III ES

            VULdb / VULdb ES

            VULdb-II ES

            VULone ES / VULone 2005 ES

            Momentum VULone / Momentum VULone 2005

            VULcv-IV ES

            VULdb-IV ES

            AssetEdge VUL

            AssetEdge VUL/AssetEdge Exec VUL 2015

            VULone 2007

            VULone 2010

          
	
            LLANY Separate Account R for Flexible Premium Variable Life (811-08651)

          	
            SVUL / SVUL ES

            SVUL-II ES

            SVUL-III ES

            SVUL-IV ES/PreservationEdge SVUL

            SVULone ES

            Momentum SVULone

            SVULone 2007

          
	
            LLANY Separate Account S for Flexible Premium Variable Life (811-09257)

          	
            CVUL Series III ES

            LCV4 ES

            LCV5 ES / LCC VUL

          
	
            Lincoln Life & Annuity Flexible Premium Variable Life Account Y (811-21029)

          	
            American Legacy VULcv-III

            American Legacy VULdb-II

            American Legacy SVUL-III

            American Legacy VULcv-IV

            American Legacy VULdb-IV

            American Legacy SVUL-IV/PreservationEdge SVUL

            American Legacy AssetEdge

          

    

    Variable Annuity Insurance Separate Accounts:

    

    

    	
            Lincoln Life & Annuity Variable Annuity  Account H (811-08441)

          	
            American Legacy III

            American Legacy III B Class

            American Legacy III C Share

            American Legacy III Plus

            American Legacy III View

            American Legacy Design

            American Legacy Signature

            American Legacy Fusion

            American Legacy Series

            American Legacy Advisory

            American Legacy Target Date Income B Share

            American Legacy Target Date Income Advisory

            Shareholder’s Advantage

            Shareholder’s Advantage A Class

          
	
            Lincoln Life & Annuity Variable Annuity Account L (811-07785)

          	
            Group Variable Annuity

          
	
            Lincoln New York Account N for Variable Annuities (811-09763)

          	
            ChoicePlus Assurance (A Share)

            ChoicePlus Assurance (A Class)

            ChoicePlus Assurance (B Share)

            ChoicePlus Assurance (B Class)

            ChoicePlus Assurance (C Share)

            ChoicePlus Assurance (L Share)

            ChoicePlus Assurance (Bonus)

            ChoicePlus

            ChoicePlus II

            ChoicePlus Access

            ChoicePlus II Access

            ChoicePlus II Advance

            ChoicePlus II Bonus

            ChoicePlus Design

            ChoicePlus Signature

            ChoicePlus Fusion

            ChoicePlus Series

            ChoicePlus Prime

            ChoicePlus Advisory

            ChoicePlus Select B-Share

            Lincoln InvestmentSolutions

            Lincoln Investor Advantage

            Lincoln Investor Advantage 2018

            Lincoln Investor Advantage Fee-Based

            Lincoln Investor Advantage Advisory

            Core Income

          

    

    

    Except as otherwise specifically provided herein, the power-of-attorney granted herein shall not in any manner revoke in whole or in part any power-of-attorney
      that each person whose signature appears below has previously executed.  This power-of-attorney shall not be revoked by any subsequent power-of-attorney each person whose signature appears below may execute, unless such subsequent power specifically
      refers to this power-of-attorney or specifically states that the instrument is intended to revoke all prior general powers-of-attorney or all prior powers-of-attorney.

    

    

    This Power-of-Attorney may be executed in separate counterparts each of which when executed and delivered shall be an original; but all such counterparts shall
      together constitute one and the same instrument.  Each counterpart may consist of a number of copies, each signed by less than all, but together signed by all, of the undersigned.

    

    

    

    

    Signature                                                                                    Title

    

    

    /s/Dennis R. Glass

    
      
        	______________________________	
                President and Director

              

      

    

    Dennis R. Glass

    

    

    /s/Ellen G. Cooper

    ______________________________                                         
      Executive Vice President, Chief Investment Officer Ellen G. Cooper  and Director

    

    

    /s/Randal J. Freitag

    ______________________________                                         
      Executive Vice President; Chief Financial Officer Randal J. Freitag  and Director

    

    

    /s/Christine A. Janofsky

    ______________________________                                      
      Senior Vice President; Chief Accounting Officer Christine A. Janofsky  and Controller

    

    

    /s/Lisa M. Buckingham

    ______________________________                                           
      Director

    Lisa M. Buckingham

    

    

    /s/George W. Henderson

    ______________________________                                         
      Director

    George W. Henderson, III

    

    

    /s/ Mark E. Konen

    ______________________________                                     
      Director

    Mark E. Konen

    

    

    /s/M. Leanne Lachman

    ______________________________                                        
      Director

    M. Leanne Lachman

    

    

    /s/Louis G. Maroccia

    ______________________________                                         
      Director

    Louis G. Marcoccia

    

    

    /s/Patrick S. Pittard

    _______________________________                                                                                                  Director

    Patrick S. Pittard

    

    

    
      
        

    

    

    

    We, Delson R. Campbell, Scott C. Durocher, Kimberly A. Genovese, Daniel P. Herr, Donald E. Keller, Michelle Grindle, Jeffrey L. Smith, Jassmin McIver-Jones,
      Carolyn Augur and John D. Weber, have read the foregoing Power of Attorney.  We are the person(s) identified therein as agent(s) for the principal named therein.  We acknowledge our legal responsibilities.

    

    

    

    

    /s/Delson R. Campbell                                                                                                                              /s/Scott C. Durocher

    ____________________________________                                      
      ________________________________

    Delson R. Campbell                                                                                                                              Scott C. Durocher

    

    

    /s/Kimberly A. Genovese                                                                                                                /s/Daniel P. Herr

    ____________________________________                                        
      ________________________________

    Kimberly A. Genovese                                                                                                                              Daniel P. Herr

    

    

    /s/Donald E. Keller                                                                                                                /s/Michelle Grindle

    ____________________________________                                         
      ________________________________

    Donald E. Keller                                                                                                                Michelle Grindle

    

    

    /s/Jeffrey L. Smith                                                                                                                /s/John D. Weber

    ____________________________________                                          
      ________________________________

    Jeffrey L. Smith                                                                                                                              John D. Weber

    

    

    /s/Jassmin McIver-Jones                                                                                                                /s/Carolyn Augur

    ____________________________________                                           
      ________________________________

    Jassmin McIver-Jones                                                                                                                              Carolyn Augur

    

    

    

    

    

    

    

    

    

    

    Version:  February 2020

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]